A Phase 4 interventional study of Dexamethasone Sodium Phosphate and Ropivacaine Hydrochloride Inj 2 mg/ml in Postoperative Pain and Nerve Block, sponsored by Tampere University Hospital. Completed at 1 site in Finland. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-11-28.
Sponsored by Tampere University Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing dexamethasone phosphate in Pain, Postoperative — none open to participants now, none under way, none of them phase 3. dexamethasone phosphate · Pain, Postoperative.
Among the 10 studies testing dexamethasone phosphate in Pain, Postoperative, this one is the 7th largest by enrollment, is one of 3 that started in 2017, is one of 4 in phase 4, and was the 5th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →None of the 10 studies testing dexamethasone phosphate in Pain, Postoperative is open now. The open studies under Pain, Postoperative, anywhere →
dexamethasone phosphate: first FDA approval 1959 (DECADRON), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 90 across the 10 interventional studies. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 9 most frequent:
Tampere University Hospital is the lead sponsor of 212 studies on the registry; 56 are open to participants now.
10 studies in Pain, Postoperative by Tampere University Hospital: 1 open now, 1 under way, none of them phase 3. Of 6 finished, 1 (17%) have results posted.
Among the 10 studies in Pain, Postoperative by Tampere University Hospital, this one is one of 3 that started in 2017, is one of 6 in phase 4, and was the 7th registered.
Tampere University Hospital’s Pain, Postoperative studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing dexamethasone phosphate in Pain, Postoperative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Tampere University Hospital’s 10 in Pain, Postoperative:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Effect of perineural dexamethasone on the duration of popliteal nerve block after ankle/foot surgery
This study is proposed to explore the effect of perineural dexamethasone on the duration of popliteal nerve block for analgesia after ankle surgery.
After ankle or foot arthrodesis patients need a good analgesia. Nevertheless early mobilisation and discharge are important for the healing process after surgery. Peripheral nerve blocks have provided a safe, effective method to control early postoperative pain when symptoms are most severe. Perineural dexamethasone added to local anesthetic prolongs the duration of analgesia of the perineural nerve block.
The perineural use of dexamethasone is still off-label. There is a ongoing discussion of which has better benefits, intravenous or perineural dexamethasone.
There are multiple research where the intravenous and perineural dexamethasone use has compared, but there is still a limited amount of research of low dose perineural dexamethasone versus intravenous dexamethasone.
In this study investigators compare different doses of perineural dexamethasone added to ropivacaine 2 mg/ml 20ml. After arthrodesis under spinal anaesthesia the patients receive popliteal block ropivacaine 2 mg/ml 20 ml and dexamethasone of different doses. Groups 1 to 4 has dexamethasone doses 0, 2mg, 3mg or 4 mg.
After the popliteal nerve block investigators follow postoperative pain, opiate consumption, mobilisation and long term quality of life.
Investigators goal is to find a dexamethasone dose which is as low as possible but at the same time covers the need for a good pain relief and fast recovery postoperatively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult people under ankle/foot arthrodesis as a curative therapy of ankle arthrosis or situation after ankle injury or malposition
Exclusion Criteria:
Age under 18 years Complicated diabetes mellitus Lack of finnish language skill and/or co-operation Chronic pain medication in regular use
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ropivacaine Hydrochloride Inj 2mg/ml 20 ml and Sodium Chloride 9mg/mL 1 ml perineurally
Drug: Ropivacaine Hydrochloride Inj 2 mg/ml · Drug: Sodium Chloride 9mg/mL
Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,2 ml and Sodium Chloride 9mg/mL 0,8 ml perineurally
Drug: Dexamethasone Sodium Phosphate · Drug: Ropivacaine Hydrochloride Inj 2 mg/ml · Drug: Sodium Chloride 9mg/mL
Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,4 ml and Sodium Chloride 9mg/mL 0,6 ml perineurally
Drug: Dexamethasone Sodium Phosphate · Drug: Ropivacaine Hydrochloride Inj 2 mg/ml · Drug: Sodium Chloride 9mg/mL
Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,8 ml and Sodium Chloride 9mg/mL 0,2 ml perineurally
Drug: Dexamethasone Sodium Phosphate · Drug: Ropivacaine Hydrochloride Inj 2 mg/ml · Drug: Sodium Chloride 9mg/mL
Dexamethasone injection
Also known as: Oradexon
Ropivacaine injection
Drug page: Sodium Chloride
Sodium Chloride injection
Also known as: Saline
First need of opiate
Time after surgery when the patient needs opiate for the first time
Time frame: 48 hours
Opiate consumption
Total opiate consumption after surgery
Time frame: 48 hours
Pain
Numeric rating scale NRS 0-10
Time frame: postoperatively: at 4 hours, at 8 hours,at 12 hours, at 16 hours, at 20 hours, at 24 hours, at 28 hours, 32 hours, at 36 hours, at 40 hours, at 44 hours, at 48 hours,seventh postoperative day
Mobilisation
Toe movement every 4 hour during hospitalization
Time frame: postoperatively: at 4 hours, at 8 hours,at 12 hours, at 16 hours, at 20 hours, at 24 hours, at 28 hours, 32 hours, at 36 hours, at 40 hours, at 44 hours, at 48 hours
Blood glucose
Blood glucose every 4 hour during hospitalization
Time frame: postoperatively: at 4 hours, at 8 hours,at 12 hours, at 16 hours, at 20 hours, at 24 hours
Quality of life (EQ-5D-3L) -query
Time frame: Before operation and 6-8 weeks, 6 months, 12 months postoperatively
McGill -pain query
Time frame: Before operation and 6-8 weeks, 6 months, 12 months postoperatively
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2017 to primary completion in Nov 2023, 72 months.
Of 532 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 72 months is above that.
Counting every sponsor, half of 542 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone phosphate